- Notification that Annual Report will be submitted late (NT 10-K)
01 Avril 2009 - 5:51PM
Edgar (US Regulatory)
SEC FILE
NUMBER: 000-30239
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
(Check One): [X] Form
10-K [ ] Form 20-F [ ] Form 11-K [ ] Form
10-Q [ ] Form 10-D
[ ] Form N-SAR [ ] Form
N-CSR
For
Period Ended: December 31, 2008
[ ]
Transition Report on Form 10-K
[ ]
Transition Report on Form 20-F
[ ]
Transition Report on Form 11-K
[ ]
Transition Report on Form 10-Q
[ ]
Transition Report on Form N-SAR
For the
Transition Period Ended:
Read Attached Instruction
Sheet Before Preparing Form.
Please Print or
Type.
Nothing
in this form shall be construed to imply that the Commission has verified
any information contained herein.
|
If the
notification relates to a portion of the filing checked above, identify the
Item(s) to which the notification relates:
PART I - REGISTRANT
INFORMATION
Full Name
of Registrant
Former
Name if Applicable
8909 West Olympic Boulevard, Suite 208
Address
of Principal Executive Office
(Street and
Number)
Beverly Hills, California 90211
City,
State and Zip Code
PART II - RULES
12b-25(b) AND (c)
If the
subject report could not be filed without unreasonable effort or expense and the
registrant seeks relief pursuant to Rule 12b-25(b), the following should be
completed. (Check box if appropriate)
|
(a)
|
The
reasons described in reasonable detail in Part III of this form could
not be eliminated without unreasonable effort or
expense;
|
[x]
|
(b)
|
The
subject annual report, semi-annual report; transition report on Form 10-K,
Form 20-F, 11-K, Form N-SAR, or portion thereof, will be filed on or
before the fifteenth calendar day following the prescribed due date; or
the subject quarterly report or transition report on Form 10-Q, or subject
distribution report on Form 10-D, or portion thereof, will be filed on or
before the fifth calendar day following the prescribed due date;
and
|
|
(c)
|
The
accountant's statement or other exhibit required by Rule 12b-25(c) has
been attached if applicable.
|
PART III - NARRATIVE
State
below in reasonable detail the reasons why the Form 10-K, 20-F, 11-K, 10-Q,
10-D, N-SAR, N-CSR or the transition report or portion thereof, could not be
filed within the prescribed time period. (Attach Extra Sheets If
Needed)
The
Company’s accounting consultant was not able to complete the financial
statements in time for the Company’s auditor to complete the audit on a timely
basis. As a result the 10-KSB could not be filed timely.
PART IV - OTHER
INFORMATION
(1)
|
Name
and telephone number of person to contact in regard to this
notification
|
Robert N.
Wilkinson
|
(801)
|
533-9645
|
(Name)
|
(Area
Code)
|
(Telephone
Number)
|
(2)
|
Have
all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940 during the preceding 12 months (or for such shorter) period
that the registrant was required to file such reports) been
filed? If answer is no, identify report(s).
|
[x]
Yes [ ] No
|
|
|
|
(3)
|
Is
it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion
thereof?
|
[ ]
Yes [x] No
|
If so,
attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.
Amexdrug
Corporation.
(Name of
Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto
duly authorized.
Date
March
31, 2009
|
By
|
/s/
Jack Amin
|
|
|
|
Jack
Amin, President and Chief Executive Officer
|
|
INSTRUCTION: The
form may be signed by an executive officer of the registrant or by any other
duly authorized representative. The name and title of the person
signing the form shall be typed or printed beneath the signature. If
the statement is signed on behalf of the registrant by an authorized
representative (other than an executive officer), evidence of the
representative's authority to sign on behalf of the registrant shall be filed
with the form.
ATTENTION
|
Intentional
Misstatements or omissions of fact constitute Federal Criminal Violations
(See 18 U.S.C. 1001).
|
AmexDrug (CE) (USOTC:AXRX)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
AmexDrug (CE) (USOTC:AXRX)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024